Get started
Dynavax Technologies CorporationDynavax Technologies CorporationDynavax Technologies Corporation

Dynavax Technologies Corporation

No trades
OverviewFinancialsDocumentsCommunityTechnicalsForecastsSeasonalsBonds

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.53 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.2795 EUR
Net income (FY)
‪26.38 M‬ EUR
Revenue (FY)
‪267.81 M‬ EUR
Shares float
‪116.47 M‬
Beta (1Y)
0.46

Employees


Employees (FY)
405
Change (1Y)
−3 −0.74%
Revenue / Employee (1Y)
‪661.27 K‬ EUR
Net income / Employee (1Y)
‪65.14 K‬ EUR

About Dynavax Technologies Corporation


Sector
Health Technology
Industry
Biotechnology
CEO
Ryan Spencer
Website
dynavax.com
Headquarters
Emeryville
Founded
1996
IPO date
Feb 19, 2004
Identifiers
2
ISIN US2681582019
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Check out other big names from the same industry as A12EV9.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


DVAX5420600
Dynavax Technologies Corporation 2.5% 15-MAY-2026
Yield to maturity
—
Maturity date
May 15, 2026

See all A12EV9 bonds 

Frequently Asked Questions


The current price of A12EV9 is 13.0300 EUR — it has increased by 0.23% in the past 24 hours. Watch Dynavax Technologies Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LS exchange Dynavax Technologies Corporation stocks are traded under the ticker A12EV9.
A12EV9 reached its all-time high on Dec 28, 2025 with the price of 13.2500 EUR, and its all-time low was 7.8900 EUR and was reached on Sep 13, 2025. View more price dynamics on A12EV9 chart.
See other stocks reaching their highest and lowest prices.
A12EV9 stock is 0.23% volatile and has beta coefficient of 0.46. Track Dynavax Technologies Corporation stock price on the chart and check out the list of the most volatile stocks — is Dynavax Technologies Corporation there?
Today Dynavax Technologies Corporation has the market capitalization of ‪1.53 B‬, it has increased by 1.16% over the last week.
Yes, you can track Dynavax Technologies Corporation financials in yearly and quarterly reports right on TradingView.
Dynavax Technologies Corporation is going to release the next earnings report on Feb 19, 2026. Keep track of upcoming events with our Earnings Calendar.
A12EV9 earnings for the last quarter are 0.18 EUR per share, whereas the estimation was 0.11 EUR resulting in a 66.57% surprise. The estimated earnings for the next quarter are 0.07 EUR per share. See more details about Dynavax Technologies Corporation earnings.
Dynavax Technologies Corporation revenue for the last quarter amounts to ‪80.85 M‬ EUR, despite the estimated figure of ‪80.11 M‬ EUR. In the next quarter, revenue is expected to reach ‪69.90 M‬ EUR.
A12EV9 net income for the last quarter is ‪22.95 M‬ EUR, while the quarter before that showed ‪15.89 M‬ EUR of net income which accounts for 44.39% change. Track more Dynavax Technologies Corporation financial stats to get the full picture.
No, A12EV9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 13, 2026, the company has 405 employees. See our rating of the largest employees — is Dynavax Technologies Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Dynavax Technologies Corporation EBITDA is ‪15.92 M‬ EUR, and current EBITDA margin is 1.42%. See more stats in Dynavax Technologies Corporation financial statements.
Like other stocks, A12EV9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Dynavax Technologies Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Dynavax Technologies Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Dynavax Technologies Corporation stock shows the buy signal. See more of Dynavax Technologies Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.